Vanguard Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$402K Hold
33,732
– – ﹤0.01% 2262
2026
Q2
$816K Buy
33,732
+13,271
+65% +$251K ﹤0.01% 1986
2026
Q1
$337K Buy
+20,461
New +$391K ﹤0.01% 2262

Other funds holding GLUE

Vanguard Asset Management's GLUE Position: Q3 2026 in Review

Vanguard Asset Management held its Monte Rosa Therapeutics (GLUE) position steady in Q3 2026 at 33,732 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #2262.

Vanguard Asset Management first reported a position in GLUE in Q1 2026 and has held it in 3 quarters since. The position peaked at $816K in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Vanguard Asset Management held 33,732 shares of Monte Rosa Therapeutics worth $402K as of Q3 2026.
  • Vanguard Asset Management left its Monte Rosa Therapeutics share count unchanged in Q3 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #2262 holding.
  • Vanguard Asset Management first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's Monte Rosa Therapeutics position peaked at $816K in Q2 2026.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.